← Leaderboards
Jordi Rodon Ahnert
University Of Oklahoma Hlth Sciences Ctr
$390,833
Attributed
$1,172,498
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $420.4K · FY2023–25$500K$375K$250K$125K$0
'23
'24
'25
Funding mix
By agency
NIH$1,172,498 · 2
By mechanism
R01$752,098 · 1
R21$420,400 · 1
Top collaborators
- Blaine H. M. Mooers2 shared
- Jie Wu2 shared
- Mark T Bedford1 shared
- Han Xu1 shared
Most similar at University Of Oklahoma Hlth Sciences Ctr
Same institution · by research overlap
- Doris Mangiaracina Benbrook$6,963,868
- Adam Zlotnick$11,682,701
- Blaine H. M. Mooers$2,541,882
- Kamiya Mehla$1,153,907
- Vivek Subbiah$600,026
Others in their field
Other Rising Stars on “Cells”
- Mari Ostendorf · University Of Washington$51,931,230
- Sabrina Paganoni · Massachusetts General Hospital$30,122,905
- Suma Babu · Massachusetts General Hospital$30,122,905
- Supriya Menezes · The Emmes Company, Llc$25,277,032
- Jinsy Andrews · Columbia University Health Sciences$21,294,649
- Michelle Rives · Baylor College Of Medicine$20,650,593
Research focus
CellsIn VivoNeoplastic CellTumorResistanceNon-Small-Cell Lung CarcinomaInhibitorMalignant NeoplasmsPre-Clinical ModelSolid NeoplasmGenerationsResponseFoundationsPharmaceutical PreparationsComplexGenesInsightBypassEffectiveness EvaluationDrug StructureAnimalsDrug ToleranceBiologicalCell Free Dna
Grant awards (3)
Exploratory studies of cellular resistance to MTA-cooperative PRMT5 inhibitors in MTAP-loss tumors.$420,400
R21 · FY2025 · CA · contact PI
Blocking tumor progression in therapy-responsive RET aberration-associated cancer$369,899
R01 · FY2024 · CA
Blocking tumor progression in therapy-responsive RET aberration-associated cancer$382,199
R01 · FY2023 · CA